Penumbra reported Q4 2025 revenue of USD 385.4 million, up 22.1%, and FY 2025 revenue of USD 1.4 billion, up 17.5%. Q4 operating income was USD 59.2 million (15.4% operating margin) and net income was USD 47.3 million (12.3% net income margin), while FY operating income was USD 189.2 million (13.5% operating margin) and net income was USD 177.7 million (12.7% net income margin). Adjusted EBITDA was USD 79.1 million in Q4 (20.5% margin) and USD 266.8 million for FY (19.0% margin). In Q4, U.S. thrombectomy revenue was USD 203.1 million, up 12.4%, and FY U.S. thrombectomy revenue was USD 771.5 million, up 19.3%. Q4 thrombectomy revenue totaled USD 254.7 million, up 15.7%, and embolization and access revenue was USD 130.7 million, up 37.0%; for FY, thrombectomy revenue was USD 947.9 million, up 16.2%, and embolization and access revenue was USD 455.7 million, up 20.2%. Penumbra said it will not provide FY 2026 guidance or host an earnings conference call due to the proposed acquisition by Boston Scientific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF90192) on February 25, 2026, and is solely responsible for the information contained therein.